Prostaglandin E receptor subtype 2 (EP2) antagonists can be another potential therapeutic target for aneurysm suppression by inhibiting the prostaglandin E2-EP2-NF-kB signaling in macrophages [23]. The gene discussed is NFKB1; the disease is aneurysm.